Affirm Al News Today

Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings.

Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis.

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.

A panel of expert oncologists discuss the underlying rationale and potential role for CAR T therapy in patients with AL amyloidosis.

A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study.

A panel of expert oncologists explore the ongoing AFFIRM-AL trial, examining birtamimab in patients diagnosed with Mayo stage IV AL amyloidosis.

A panel of expert oncologists discuss the importance of cardiac staging for patients with AL amyloidosis and it’s role in guiding overall treatment.

Faculty delve into potential challenges related to the management of patients with AL amyloidosis and cardiac involvement, discussing the associated prognostic implications.

Faculty share insights into the treatment strategies using CD-38-directed monoclonal antibodies in patients with AL amyloidosis.

Jeffrey Zonder, MD provides an overview of treatment strategies using monoclonal antibodies for the treatment of AL amyloidosis.